FACULTY

Jennifer Chan, MD, MPH
Clinical Director, Gastrointestinal Cancer Center
Director, Program in Carcinoid and Neuroendocrine Tumors
Institute Physician
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

PROGRAM OVERVIEW

This Virtual Reality Room is designed to help learners appropriately select treatment for advanced NETs; understand criteria for referral based on tumor characteristics; evaluate evidence-based strategies for sequencing SSAs, PRRT, and targeted therapies to optimize patient outcomes; and assess clinical trial data to integrate of current and emerging therapies for high-grade NETs into clinical practice.

TARGET AUDIENCE

This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, nuclear medicine specialists, advanced healthcare practitioners, endocrinologists, nurses, and other HCPs involved in the multidisciplinary treatment of patients with neuroendocrine tumors.

LEARNING OBJECTIVES

On completing of this program, attendees should be able to:

• Determine appropriate treatment selection for advanced NETs and criteria for referral to an expert center based on tumor biology and clinical characteristics
• Evaluate evidence-based strategies for sequencing SSAs, PRRT, and targeted therapies to optimize patient outcomes
• Analyze recent clinical trial data to integrate current and emerging therapies for high-grade NETs into clinical practice

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this activity for a maximum of .25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, SVP, Operations for Med Learning Group, has nothing to disclose.
• Nicolas Applyrs, DO, independent medical reviewer, has nothing to disclose.
• Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Daniel DaSilva, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
• Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASED DATE: May 31, 2025
EXPIRATION DATE: May 31, 2026

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.